Cabaletta Bio, Inc. Common Stock (CABA)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Cabaletta Bio, Inc. Common Stock (CABA) is listed on Nasdaq, where it has traded since October 25, 2019.
- Listed On
- Nasdaq
- Listed Since
- October 25, 2019
- Employees
- 158
- Market Cap
- $258M
About Cabaletta Bio, Inc. Common Stock
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 134 institutions reported holding CABA, with 157.9 million shares worth $490.4 million in aggregate. The largest reported holder was T. Rowe Price, with 23.3 million shares worth $72.4 million. Of the 5 largest holders listed below, all 5 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| T. Rowe Price | 23,288,581 | $72M | Added 102.12% |
| Jennison Associates | 20,033,730 | $62M | Added 123.33% |
| Bain Capital Life Sciences Investors | 17,241,445 | $54M | Added 78.17% |
| BlackRock | 10,754,701 | $33M | Added 353.21% |
| Vanguard | 9,801,946 | $30M | Added 110.6% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CABA?
Cabaletta Bio, Inc. Common Stock (CABA) is listed on Nasdaq, where it has traded since October 25, 2019.
Who are the largest institutional holders of CABA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CABA were T. Rowe Price, Jennison Associates and Bain Capital Life Sciences Investors.
How many institutions own CABA?
134 institutions reported a position in CABA for the quarter ended June 30, 2026, worth $490.4 million in total.
Did institutions buy or sell CABA last quarter?
Of the 5 largest reported holders, all 5 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for CABA.
Every reported institutional holder, plus insider and congressional trades in CABA, on SentiSense.